Unknown

Dataset Information

Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone.


ABSTRACT: Friedreich's Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.

SUBMITTER: Ghanekar SD 

PROVIDER: S-EPMC6800542 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature